Statin Audit
•
0 likes•634 views
An audit of 654 patients aged 40-75 on statins for primary prevention of cardiovascular disease found that the majority had a 10-year CVD risk of less than 20%, suggesting overtreatment with statins. The audit recommends only prescribing statins for primary prevention if a patient's 10-year CVD risk is greater than 20%, as calculated by an established risk calculator, and to document the risk assessment and reasoning in the patient's notes.
Report
Share
Report
Share
Recommended
Kareem William FHD Stroke Risk Reduction Presentation
This document discusses reducing stroke risk in males through improved cholesterol and blood pressure management. It presents the case of a 59-year-old male with a history of stroke, hypertension, sleep apnea and obesity. His ASCVD 10-year risk is calculated at 12.9% and lifetime risk at 50%. The document then reviews evidence that education programs can improve medication compliance and lifestyle changes to lower stroke risk. It proposes a project targeting high-risk males over 40 through automated ASCVD risk scoring in medical records and patient education classes to enhance long-term outcomes monitoring and management of cholesterol and blood pressure.
Prevention guidelines cholesterol
1. The document summarizes 10 key points from expert panel recommendations for treating blood cholesterol to reduce cardiovascular risk.
2. It identifies four groups that benefit from statin therapy based on extensive evidence: those with clinical cardiovascular disease, very high LDL levels, diabetes with moderately high LDL, and those at high 10-year risk of cardiovascular disease.
3. The panel recommends using the new Pooled Cohort Equations risk calculator to estimate 10-year cardiovascular risk and determine who benefits most from statin therapy.
Session 1 presentation w live poll
This document summarizes a case of a 56-year-old obese male patient who presented with excessive daytime sleepiness and snoring. A polysomnography (PSG) study found that the patient had obstructive sleep apnea (OSA) but developed central sleep apnea (CSA) events after starting continuous positive airway pressure (CPAP) therapy, indicating a diagnosis of complex sleep apnea. Complex sleep apnea is defined as the emergence or persistence of central sleep apnea events following or during treatment of obstructive sleep apnea.
Ordinal or scaled data practice problems (2)
- The document describes two practice problems involving analysis of patient systolic blood pressure data.
- The first problem involves finding the average of national percentile rankings, which is ordinal data as the intervals between rankings are not equal.
- The second problem involves reporting the lowest and highest blood pressure readings in a data set, which is scaled data as blood pressure has equal intervals.
2013 prevention guidelines cholesterol slide set 4
This document summarizes the 2013 ACC/AHA guidelines for treating blood cholesterol to reduce cardiovascular risk. It provides an overview of the guideline development process, which included a systematic review of randomized controlled trials and development of recommendations based on evidence. The guidelines emphasize adherence to lifestyle changes and identify four statin benefit groups. They also discuss assessing risk and initiating appropriate intensity statin therapy, while noting a lack of evidence for specific cholesterol treatment targets.
Dyslipidemia 2016
The document discusses guidelines from the Canadian Cardiovascular Society for the management of dyslipidemia to prevent cardiovascular disease. It provides recommendations on screening, risk assessment, pharmacological treatment indications and targets, and monitoring. Key points include recommending non-fasting lipid screening, treating high risk groups with statins to achieve an LDL-C target of <2.0 mmol/L, and using ezetimibe as second-line therapy if targets are not reached with statins alone. The guidelines were developed using the GRADE process and are intended to help optimize dyslipidemia management and reduce cardiovascular risk.
Never Waste a Crisis
Healthcare Innovation Summit 2016: Keynote speaker Dr. Jeffrey Brenner shares only the best recommendations during a deep economic and healthcare crisis affecting Puerto Rico. Despite these circumstances, VarMed has managed to build and effectively manage the largest Super-Utilizer program. Additional data on health costs and disparities are shared in this presentation.
Best recruitment strategies for elderly patients in clinical trials
Clinical research breakthroughs would be impossible without people who agree to participate. Depending on the nature of the research that’s being conducted, different types of patient population are needed. Even though some research conditions and treatments might apply only to the younger population, most of them will require both younger and older people, since the variety of these different age groups will provide better study results. Another reason why elderly patients are much-needed participants in clinical research is the fact that approximately one-third of all medications are consumed by them. Taking into consideration that people over 65 consist only 13% of the population (more or less), one-third of all medication being used by them is a large number. For this reason, elderly patients are invaluable in clinical research.
Recommended
Kareem William FHD Stroke Risk Reduction Presentation
This document discusses reducing stroke risk in males through improved cholesterol and blood pressure management. It presents the case of a 59-year-old male with a history of stroke, hypertension, sleep apnea and obesity. His ASCVD 10-year risk is calculated at 12.9% and lifetime risk at 50%. The document then reviews evidence that education programs can improve medication compliance and lifestyle changes to lower stroke risk. It proposes a project targeting high-risk males over 40 through automated ASCVD risk scoring in medical records and patient education classes to enhance long-term outcomes monitoring and management of cholesterol and blood pressure.
Prevention guidelines cholesterol
1. The document summarizes 10 key points from expert panel recommendations for treating blood cholesterol to reduce cardiovascular risk.
2. It identifies four groups that benefit from statin therapy based on extensive evidence: those with clinical cardiovascular disease, very high LDL levels, diabetes with moderately high LDL, and those at high 10-year risk of cardiovascular disease.
3. The panel recommends using the new Pooled Cohort Equations risk calculator to estimate 10-year cardiovascular risk and determine who benefits most from statin therapy.
Session 1 presentation w live poll
This document summarizes a case of a 56-year-old obese male patient who presented with excessive daytime sleepiness and snoring. A polysomnography (PSG) study found that the patient had obstructive sleep apnea (OSA) but developed central sleep apnea (CSA) events after starting continuous positive airway pressure (CPAP) therapy, indicating a diagnosis of complex sleep apnea. Complex sleep apnea is defined as the emergence or persistence of central sleep apnea events following or during treatment of obstructive sleep apnea.
Ordinal or scaled data practice problems (2)
- The document describes two practice problems involving analysis of patient systolic blood pressure data.
- The first problem involves finding the average of national percentile rankings, which is ordinal data as the intervals between rankings are not equal.
- The second problem involves reporting the lowest and highest blood pressure readings in a data set, which is scaled data as blood pressure has equal intervals.
2013 prevention guidelines cholesterol slide set 4
This document summarizes the 2013 ACC/AHA guidelines for treating blood cholesterol to reduce cardiovascular risk. It provides an overview of the guideline development process, which included a systematic review of randomized controlled trials and development of recommendations based on evidence. The guidelines emphasize adherence to lifestyle changes and identify four statin benefit groups. They also discuss assessing risk and initiating appropriate intensity statin therapy, while noting a lack of evidence for specific cholesterol treatment targets.
Dyslipidemia 2016
The document discusses guidelines from the Canadian Cardiovascular Society for the management of dyslipidemia to prevent cardiovascular disease. It provides recommendations on screening, risk assessment, pharmacological treatment indications and targets, and monitoring. Key points include recommending non-fasting lipid screening, treating high risk groups with statins to achieve an LDL-C target of <2.0 mmol/L, and using ezetimibe as second-line therapy if targets are not reached with statins alone. The guidelines were developed using the GRADE process and are intended to help optimize dyslipidemia management and reduce cardiovascular risk.
Never Waste a Crisis
Healthcare Innovation Summit 2016: Keynote speaker Dr. Jeffrey Brenner shares only the best recommendations during a deep economic and healthcare crisis affecting Puerto Rico. Despite these circumstances, VarMed has managed to build and effectively manage the largest Super-Utilizer program. Additional data on health costs and disparities are shared in this presentation.
Best recruitment strategies for elderly patients in clinical trials
Clinical research breakthroughs would be impossible without people who agree to participate. Depending on the nature of the research that’s being conducted, different types of patient population are needed. Even though some research conditions and treatments might apply only to the younger population, most of them will require both younger and older people, since the variety of these different age groups will provide better study results. Another reason why elderly patients are much-needed participants in clinical research is the fact that approximately one-third of all medications are consumed by them. Taking into consideration that people over 65 consist only 13% of the population (more or less), one-third of all medication being used by them is a large number. For this reason, elderly patients are invaluable in clinical research.
Dyslipidemia Guidelines 2016
1) This document provides guidelines for screening, assessing cardiovascular risk, and managing dyslipidemia from the 2016 Canadian Cardiovascular Society guidelines.
2) It recommends screening all adults aged 40-75 for lipids and assessing risk every 5 years using the Framingham Risk Score or Cardiovascular Life Expectancy Model.
3) For primary prevention, it recommends considering statin therapy for those at intermediate risk with LDL-C ≥3.5 mmol/L or other risk factors. For high risk it recommends statin therapy.
Slides-Cholesterol.ppt
The document provides guidelines from a committee for managing blood cholesterol to reduce atherosclerotic cardiovascular disease risk. It includes 10 key recommendations, such as emphasizing lifestyle changes for all ages, using high-intensity statin therapy for patients with clinical ASCVD, considering additional nonstatin drugs for very high risk patients, and assessing adherence to medication and lifestyle changes. The guidelines cover measuring cholesterol levels, risk assessment, and treatment approaches for different patient groups including those with diabetes or severe hypercholesterolemia.
Statins
This document discusses the role of statins in primary prevention of cardiovascular disease. It begins by outlining how cardiovascular disease is a leading cause of death worldwide. It then describes the pathogenesis of atherosclerosis and defines clinical forms of ASCVD. The main mechanisms of action and effects of statins on lipids are explained. The document recommends assessing cardiovascular risk and initiating statin therapy based on risk level. It also discusses risk-enhancing factors, adverse effects of statins, and contraindications. Guidelines from major cardiovascular organizations are referenced.
Statin Wars
- The document discusses guidelines for statin use in primary prevention from the 2014 ACC/AHA, including algorithms for determining statin eligibility based on estimated 10-year risk of atherosclerotic cardiovascular disease (ASCVD).
- It notes that the guidelines lower the risk threshold for statin recommendation from greater than 7.5% 10-year ASCVD risk to greater than 5% for some patients.
- Concerns raised about the guidelines include the selection of studies included in reviews and the lack of consideration of observational data or post-hoc analyses of randomized controlled trials.
Humana Preventive Health Guide
The document provides guidelines for various preventive health screenings and checkups for healthy adults, including physical exams, cholesterol/lipid screening, diabetes screening tests, blood pressure checks, and cancer screenings. It also includes vaccination and immunization guidelines for children and adults on the back page, with recommendations for different vaccines based on age. The guidelines note that individuals with family histories of diseases or other risk factors should discuss customized preventive plans with their doctors.
RIESGO CARDIOMETABOLICO
Los fármacos recomendados para iniciar el tratamiento antihipertensivo en este paciente son:
- Candesartán: por su demostrada capacidad para disminuir la hipertrofia ventricular izquierda y reducir la proteinuria, lo que es importante dado que el paciente presenta diabetes e hipertrofia ventricular.
- Telmisartán: al igual que el candesartán, ha demostrado reducir la proteinuria en pacientes diabéticos. Además, posee efecto antioxidante y antiaterogénico que son beneficiosos en este tipo de pacientes.
- V
Management of Dyslipidemia in the Elderly
Aging itself is the strongest
risk factor for nonfatal and fatal ASCVD events
Elderly population should be screened for
Main CV risk factors :
T2D , HTN , Smoking , Dyslipidemia & Obesity
Comorbidities : CKD
Geriatric conditions: Functional Impairment
What the latest lipid guidelines
say about dyslipidemia in the elderly ?
Coronary calcium scoring recommendations.Absolute risk increases with age :
The CV event rates in elderly subjects are proportionately higher than for younger subjects in primary and secondary prevention studies
Secondary prevention of events :
The effectiveness of lipid-lowering treatments—and in particular statins—is now certified in the secondary prevention of events even after the age of 75 and beyond.
Primary prevention :
The opportunity for treatment with statins in primary prevention after the age of 75 continues to represent an area of uncertainty due to the scarcity of data derived from prospective randomized studies.
Treating Cholesterol in Asian Patients: Balancing the Risk and Benefits
This document summarizes a presentation on treating cholesterol in Asians given by Dr. Jeremy Chow. It discusses the prevalence of hyperlipidemia in Singapore, challenges with statin usage in Asians including common myths, and new cholesterol targets for high-risk patients. It provides examples of managing different patient cases, including lifestyle modifications, medications such as statins and PCSK9 inhibitors, and balancing risks and benefits of treatment.
Cholesterol Management Guidelines
The document provides guidelines for cholesterol management and cardiovascular disease (CVD) risk assessment. It discusses guidelines for measuring cholesterol and lipid levels, calculating LDL and VLDL values, and assessing CVD risk. It recommends starting moderate- or high-intensity statin therapy for most adults aged 40-75 years with diabetes or LDL ≥70 mg/dL. For those without diabetes but with a CVD risk of 7.5% or higher, it recommends discussing statin therapy. The guidelines also provide recommendations for managing statin side effects, evaluating risk factors, and refining risk assessment using coronary artery calcium scoring. The main messages are to emphasize lifestyle changes, use high-intensity statins for high-risk patients, and consider patient risk
Lipid management 2013 acc-aha guidelines
1. The new guidelines recommend initiating moderate or high-intensity statin therapy for patients in four categories based on their cardiovascular risk, rather than targeting a specific LDL-C level.
2. The four categories are: individuals with clinical atherosclerotic cardiovascular disease, LDL-C over 190 mg/dL, diabetes between ages 40-75 with LDL-C 70-189 mg/dL, and 10-year risk over 7.5% for ages 40-75 with LDL-C 70-189 mg/dL.
3. Lipids should be measured during follow-ups to assess adherence, not to achieve a specific target level.
NACHC-Statin-Guideline-Snapshot-Generic.pptx
The document outlines guidelines from the 2018 ACC/AHA for statin management in high-risk groups. It recommends high or moderate-intensity statins for four groups: patients with clinical atherosclerotic cardiovascular disease (ASCVD), primary prevention patients with LDL-C ≥190 mg/dL, primary prevention patients with diabetes and LDL-C 70-189 mg/dL, and high-risk patients without a 10-year ASCVD risk calculation. It provides specific statin treatment recommendations for each group based on age and risk factors. The guidelines also discuss monitoring response to statins and evaluating for drug interactions.
Dyslipidemia protocol
This document provides guidelines for the diagnosis and management of dyslipidemia for adults over 18 years old. It was developed by a multidisciplinary task force and has been reviewed and approved regularly since 1999. The guidelines establish screening recommendations and lipid treatment goals based on a patient's risk level. They provide a sequence of medication recommendations depending on a patient's lipid patterns. The guidelines are intended to help clinicians manage dyslipidemia and reduce patients' risk of coronary heart disease.
ASCVD Risk and Effect of Hypertension
This document summarizes a presentation about a 63-year-old African American female patient with hypertension, diabetes, and heart failure. Her 10-year ASCVD risk is calculated at 38.7% based on her medical history and lab results. The presentation reviews community resources that could help improve her condition, such as programs to enhance health literacy and encourage weight loss through text messaging. It also analyzes aggregate panel data on hypertension treatment and risk factors from other patients. Finally, it proposes a grant-funded project to implement a health literacy program and distribute home blood pressure monitors to hypertensive patients at a free clinic to improve blood pressure control and reduce cardiovascular risk.
Old vs new targets april 2015
This document summarizes guidelines for cholesterol treatment and clinical trials evaluating lipid targets. It discusses the ATP III guidelines, major trials after ATP III including TNT, JUPITER, ACCORD-LIPID, and AIM-HIGH. It then reviews the 2013 ACC/AHA cholesterol treatment guidelines, including the 4 groups that benefit from statins, ASCVD risk assessment, and future directions. Clinical cases are used to illustrate guideline recommendations for statin treatment based on a patient's risk factors.
Dyslipidemia overview 2017
Dyslipidemia, specially high LDL cholesterol is the key risk factor for cardiovascular diseases. The presentation discusses metabolism and structure of lipoproteins, their screening and interpretation, risk assessment methods, targets for various lipoproteins and its step by step treatment.
Acc 2018 guidelines on lipids
The new 2018 ACC/AHA Guideline on the Management of Blood Cholesterol allows for more personalized care for patients compared to its 2013 predecessor
Healthy 100
This talk is to promote population health via preventive medicine, immunization, healthy life style, exercise, food, decreased diabetes, hypertension and cancer risks
ueda2013 primary prevention-d.lobna
The JUPITER trial was stopped early due to clear evidence of benefit from rosuvastatin treatment. The trial aimed to test whether rosuvastatin could reduce cardiovascular events in apparently healthy people with normal LDL cholesterol but high hsCRP. Over 17,000 participants were randomized to rosuvastatin 20mg or placebo. After almost 2 years, rosuvastatin showed a highly significant 44% reduction in the primary cardiovascular endpoint compared to placebo, demonstrating its benefit in primary prevention. This clear benefit led to the trial being stopped early.
Dyslipidemia
This patient presents with multiple metabolic risk factors including obesity, elevated triglycerides and fasting blood glucose, and a family history of diabetes. While she does not meet the criteria for metabolic syndrome, her 10-year risk of heart disease is elevated. Her LDL cholesterol goal according to NCEP guidelines is less than 160 mg/dL. Fasting glucose would be most influential in determining her treatment plan given her risk factors.
Lipid guidelines
This document provides guidelines for the practice of treating dyslipidemia. It defines dyslipidemia as abnormal lipid levels measured in a blood sample, which can include hypercholesterolemia, low HDL levels, or hypertriglyceridemia. The document discusses various classification systems for different lipid levels and cardiovascular risk factors. It recommends screening and treatment approaches based on a patient's risk level as assessed by tools like the Pooled Cohort Equation or UKPDS risk engine. Key treatment involves starting statin therapy matched to a patient's risk level and potential side effects. The document also provides guidance on screening for familial hypercholesterolemia.
More Related Content
Similar to Statin Audit
Dyslipidemia Guidelines 2016
1) This document provides guidelines for screening, assessing cardiovascular risk, and managing dyslipidemia from the 2016 Canadian Cardiovascular Society guidelines.
2) It recommends screening all adults aged 40-75 for lipids and assessing risk every 5 years using the Framingham Risk Score or Cardiovascular Life Expectancy Model.
3) For primary prevention, it recommends considering statin therapy for those at intermediate risk with LDL-C ≥3.5 mmol/L or other risk factors. For high risk it recommends statin therapy.
Slides-Cholesterol.ppt
The document provides guidelines from a committee for managing blood cholesterol to reduce atherosclerotic cardiovascular disease risk. It includes 10 key recommendations, such as emphasizing lifestyle changes for all ages, using high-intensity statin therapy for patients with clinical ASCVD, considering additional nonstatin drugs for very high risk patients, and assessing adherence to medication and lifestyle changes. The guidelines cover measuring cholesterol levels, risk assessment, and treatment approaches for different patient groups including those with diabetes or severe hypercholesterolemia.
Statins
This document discusses the role of statins in primary prevention of cardiovascular disease. It begins by outlining how cardiovascular disease is a leading cause of death worldwide. It then describes the pathogenesis of atherosclerosis and defines clinical forms of ASCVD. The main mechanisms of action and effects of statins on lipids are explained. The document recommends assessing cardiovascular risk and initiating statin therapy based on risk level. It also discusses risk-enhancing factors, adverse effects of statins, and contraindications. Guidelines from major cardiovascular organizations are referenced.
Statin Wars
- The document discusses guidelines for statin use in primary prevention from the 2014 ACC/AHA, including algorithms for determining statin eligibility based on estimated 10-year risk of atherosclerotic cardiovascular disease (ASCVD).
- It notes that the guidelines lower the risk threshold for statin recommendation from greater than 7.5% 10-year ASCVD risk to greater than 5% for some patients.
- Concerns raised about the guidelines include the selection of studies included in reviews and the lack of consideration of observational data or post-hoc analyses of randomized controlled trials.
Humana Preventive Health Guide
The document provides guidelines for various preventive health screenings and checkups for healthy adults, including physical exams, cholesterol/lipid screening, diabetes screening tests, blood pressure checks, and cancer screenings. It also includes vaccination and immunization guidelines for children and adults on the back page, with recommendations for different vaccines based on age. The guidelines note that individuals with family histories of diseases or other risk factors should discuss customized preventive plans with their doctors.
RIESGO CARDIOMETABOLICO
Los fármacos recomendados para iniciar el tratamiento antihipertensivo en este paciente son:
- Candesartán: por su demostrada capacidad para disminuir la hipertrofia ventricular izquierda y reducir la proteinuria, lo que es importante dado que el paciente presenta diabetes e hipertrofia ventricular.
- Telmisartán: al igual que el candesartán, ha demostrado reducir la proteinuria en pacientes diabéticos. Además, posee efecto antioxidante y antiaterogénico que son beneficiosos en este tipo de pacientes.
- V
Management of Dyslipidemia in the Elderly
Aging itself is the strongest
risk factor for nonfatal and fatal ASCVD events
Elderly population should be screened for
Main CV risk factors :
T2D , HTN , Smoking , Dyslipidemia & Obesity
Comorbidities : CKD
Geriatric conditions: Functional Impairment
What the latest lipid guidelines
say about dyslipidemia in the elderly ?
Coronary calcium scoring recommendations.Absolute risk increases with age :
The CV event rates in elderly subjects are proportionately higher than for younger subjects in primary and secondary prevention studies
Secondary prevention of events :
The effectiveness of lipid-lowering treatments—and in particular statins—is now certified in the secondary prevention of events even after the age of 75 and beyond.
Primary prevention :
The opportunity for treatment with statins in primary prevention after the age of 75 continues to represent an area of uncertainty due to the scarcity of data derived from prospective randomized studies.
Treating Cholesterol in Asian Patients: Balancing the Risk and Benefits
This document summarizes a presentation on treating cholesterol in Asians given by Dr. Jeremy Chow. It discusses the prevalence of hyperlipidemia in Singapore, challenges with statin usage in Asians including common myths, and new cholesterol targets for high-risk patients. It provides examples of managing different patient cases, including lifestyle modifications, medications such as statins and PCSK9 inhibitors, and balancing risks and benefits of treatment.
Cholesterol Management Guidelines
The document provides guidelines for cholesterol management and cardiovascular disease (CVD) risk assessment. It discusses guidelines for measuring cholesterol and lipid levels, calculating LDL and VLDL values, and assessing CVD risk. It recommends starting moderate- or high-intensity statin therapy for most adults aged 40-75 years with diabetes or LDL ≥70 mg/dL. For those without diabetes but with a CVD risk of 7.5% or higher, it recommends discussing statin therapy. The guidelines also provide recommendations for managing statin side effects, evaluating risk factors, and refining risk assessment using coronary artery calcium scoring. The main messages are to emphasize lifestyle changes, use high-intensity statins for high-risk patients, and consider patient risk
Lipid management 2013 acc-aha guidelines
1. The new guidelines recommend initiating moderate or high-intensity statin therapy for patients in four categories based on their cardiovascular risk, rather than targeting a specific LDL-C level.
2. The four categories are: individuals with clinical atherosclerotic cardiovascular disease, LDL-C over 190 mg/dL, diabetes between ages 40-75 with LDL-C 70-189 mg/dL, and 10-year risk over 7.5% for ages 40-75 with LDL-C 70-189 mg/dL.
3. Lipids should be measured during follow-ups to assess adherence, not to achieve a specific target level.
NACHC-Statin-Guideline-Snapshot-Generic.pptx
The document outlines guidelines from the 2018 ACC/AHA for statin management in high-risk groups. It recommends high or moderate-intensity statins for four groups: patients with clinical atherosclerotic cardiovascular disease (ASCVD), primary prevention patients with LDL-C ≥190 mg/dL, primary prevention patients with diabetes and LDL-C 70-189 mg/dL, and high-risk patients without a 10-year ASCVD risk calculation. It provides specific statin treatment recommendations for each group based on age and risk factors. The guidelines also discuss monitoring response to statins and evaluating for drug interactions.
Dyslipidemia protocol
This document provides guidelines for the diagnosis and management of dyslipidemia for adults over 18 years old. It was developed by a multidisciplinary task force and has been reviewed and approved regularly since 1999. The guidelines establish screening recommendations and lipid treatment goals based on a patient's risk level. They provide a sequence of medication recommendations depending on a patient's lipid patterns. The guidelines are intended to help clinicians manage dyslipidemia and reduce patients' risk of coronary heart disease.
ASCVD Risk and Effect of Hypertension
This document summarizes a presentation about a 63-year-old African American female patient with hypertension, diabetes, and heart failure. Her 10-year ASCVD risk is calculated at 38.7% based on her medical history and lab results. The presentation reviews community resources that could help improve her condition, such as programs to enhance health literacy and encourage weight loss through text messaging. It also analyzes aggregate panel data on hypertension treatment and risk factors from other patients. Finally, it proposes a grant-funded project to implement a health literacy program and distribute home blood pressure monitors to hypertensive patients at a free clinic to improve blood pressure control and reduce cardiovascular risk.
Old vs new targets april 2015
This document summarizes guidelines for cholesterol treatment and clinical trials evaluating lipid targets. It discusses the ATP III guidelines, major trials after ATP III including TNT, JUPITER, ACCORD-LIPID, and AIM-HIGH. It then reviews the 2013 ACC/AHA cholesterol treatment guidelines, including the 4 groups that benefit from statins, ASCVD risk assessment, and future directions. Clinical cases are used to illustrate guideline recommendations for statin treatment based on a patient's risk factors.
Dyslipidemia overview 2017
Dyslipidemia, specially high LDL cholesterol is the key risk factor for cardiovascular diseases. The presentation discusses metabolism and structure of lipoproteins, their screening and interpretation, risk assessment methods, targets for various lipoproteins and its step by step treatment.
Acc 2018 guidelines on lipids
The new 2018 ACC/AHA Guideline on the Management of Blood Cholesterol allows for more personalized care for patients compared to its 2013 predecessor
Healthy 100
This talk is to promote population health via preventive medicine, immunization, healthy life style, exercise, food, decreased diabetes, hypertension and cancer risks
ueda2013 primary prevention-d.lobna
The JUPITER trial was stopped early due to clear evidence of benefit from rosuvastatin treatment. The trial aimed to test whether rosuvastatin could reduce cardiovascular events in apparently healthy people with normal LDL cholesterol but high hsCRP. Over 17,000 participants were randomized to rosuvastatin 20mg or placebo. After almost 2 years, rosuvastatin showed a highly significant 44% reduction in the primary cardiovascular endpoint compared to placebo, demonstrating its benefit in primary prevention. This clear benefit led to the trial being stopped early.
Dyslipidemia
This patient presents with multiple metabolic risk factors including obesity, elevated triglycerides and fasting blood glucose, and a family history of diabetes. While she does not meet the criteria for metabolic syndrome, her 10-year risk of heart disease is elevated. Her LDL cholesterol goal according to NCEP guidelines is less than 160 mg/dL. Fasting glucose would be most influential in determining her treatment plan given her risk factors.
Lipid guidelines
This document provides guidelines for the practice of treating dyslipidemia. It defines dyslipidemia as abnormal lipid levels measured in a blood sample, which can include hypercholesterolemia, low HDL levels, or hypertriglyceridemia. The document discusses various classification systems for different lipid levels and cardiovascular risk factors. It recommends screening and treatment approaches based on a patient's risk level as assessed by tools like the Pooled Cohort Equation or UKPDS risk engine. Key treatment involves starting statin therapy matched to a patient's risk level and potential side effects. The document also provides guidance on screening for familial hypercholesterolemia.
Similar to Statin Audit (20)
Treating Cholesterol in Asian Patients: Balancing the Risk and Benefits
Treating Cholesterol in Asian Patients: Balancing the Risk and Benefits
Recently uploaded
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
This quiz was conducted as a promotional event for the 2024 Annual Meet of Kerala Chapter of API.
More than 20 participants took part everyday !
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Cervical Disc Arthroplasty ORSI 2024.pptx
Indication and installation of a mobile cervical disc prosthesis. Benefits of the PRODISC C VIVO mobile disc prosthesis (Centinel Spine)
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...Kosmoderma Academy Of Aesthetic Medicine
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
NARCOTICS- POLICY AND PROCEDURES FOR ITS USE
This document outlines policies and procedures for handling narcotic and controlled drugs in NABH accredited hospitals.
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS). Parc Taulí. Sabadell
The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
10 Benefits an EPCR Software should Bring to EMS Organizations
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
CLEAR ALIGNER THERAPY IN ORTHODONTICS .pptx
Dr. ZANAB FARHEEN FAYAZ ,MDS(ORTHODONTICS & DENTOFACIAL ORTHOPEDICS ).
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Recently uploaded (20)
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Statin Audit
- 1. Audit: use of statins for the primary prevention of CVD Jim Hare and Charles Read
- 9. Methods Search strategy Everyone on a statin Aged 40-75 Excluding diabetics, familial hypercholesterolaemia Excluding those with existing CVD This returned 654 patients. We took a random sample of 10%
- 10. Assessment of CVD RiSK
- 11. Results 12/65 (18%) were not eligible 35/53 (66%) had a 10-year CVD risk of <20% 14/53 (26%) had a 10-year CVD risk of <20% but >15% 12/53 (23%) had a 10-year CVD risk of <10% Smoking status was often difficult to determine
- 12. Take home messages Statins are good but... They have their side effects NNT=170 for four years In those without CVD, only start a statin if the 10-year risk is >20% Use an established calculator Record your reasoning in the notes (making reference to all risk factors)
Editor's Notes
- This was a meta analysis in the JAMA that showed that statin use was not associated with an increased risk of cancer.